GET DAILY SIGNALSAshland (ASH) Reports 4% Revenue Growth in Q4 Fiscal 2026 but Swings to a Net Loss
Key Takeaways
- Ashland reported fourth-quarter fiscal 2026 revenue of $498 million, up 4% year over year but slightly below the consensus estimate of about $501.8 million.
- The quarter swung to a net loss of $16 million, or $0.35 per diluted share, reflecting asset impairment, restructuring, and Argentina liquidation charges.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 2% to $121 million, with an adjusted EBITDA margin of 24.3%.
- Adjusted diluted EPS excluding intangibles amortization reached $1.12, up from $1.08 in the prior-year quarter but below analyst expectations.
- Life Sciences delivered a record quarterly adjusted EBITDA margin of 35.6%, while Specialty Additives was held back by lower Hopewell plant productivity.
- Ashland issued fiscal 2027 guidance for revenue of $1.905 billion to $1.975 billion and adjusted EBITDA of $405 million to $435 million.
- For deeper coverage of ASH, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
- Discover automated trading ideas by exploring Trending AI Robots.
Putting the Earnings in Context
Ashland's fourth-quarter and full-year fiscal 2026 results provide a useful checkpoint on the specialty ingredients maker's recovery path after a fiscal 2025 that included a $706 million goodwill impairment and the Avoca divestiture. The company closed fiscal 2026 with sales of $1.863 billion, up 2%, and posted a modest full-year net profit of $4 million compared with a prior-year net loss of $845 million. For investors, the report stands out for what it signals about demand trends in pharma, personal care, and coatings, along with progress on the Hopewell productivity investments. The newly issued fiscal 2027 outlook offers the first clear view on whether management sees that momentum persisting.
Breaking Down the Reported Results
For the fourth quarter ended September 30, 2026, Ashland reported sales of $498 million, a 4% increase from $478 million a year earlier, supported by a 3% volume gain and 2% higher pricing, partially offset by foreign currency effects. The figure landed just below the consensus estimate of roughly $501.8 million. The company recorded a net loss of $16 million, or $0.35 per diluted share, versus net income of $32 million, or $0.71 per share, in the prior-year quarter. The loss included an $18 million asset impairment, a $13 million cumulative translation adjustment from the liquidation of its Argentine entity, restructuring and separation costs, and an environmental reserve adjustment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On an adjusted basis, EBITDA increased 2% to $121 million, and adjusted diluted EPS excluding intangibles amortization rose to $1.12 from $1.08. Segment performance was mixed: Life Sciences sales grew 4% to $180 million with adjusted EBITDA up 16%, while Personal Care sales rose 8% to $163 million. Specialty Additives sales held flat at $131 million as lower Hopewell productivity led to a 31% drop in segment adjusted EBITDA.
Market Reaction and Investor Sentiment
Investor sentiment ahead of the report was cautiously optimistic, with consensus expectations centered on roughly $501.8 million in revenue and adjusted EPS near the low-to-mid $1.20 range. The modest top-line miss and adjusted EPS result below the Street likely tempered enthusiasm, even as the company highlighted a third consecutive quarter of year-over-year sales growth in China and record profitability in Life Sciences. The swing to a reported net loss, driven mainly by non-cash and one-time items, may generate near-term headline noise, but the company’s strong cash generation—operating cash flow of $385 million for the year—provides a more constructive signal. Post-earnings price action will probably depend on how investors balance the fiscal 2027 guidance against current estimates.
Forward Outlook and Key Factors to Monitor
Ashland's fiscal 2027 guidance calls for revenue between $1.905 billion and $1.975 billion, representing roughly 2% to 6% growth, and adjusted EBITDA between $405 million and $435 million. Management expects ongoing free cash flow conversion above 40% of adjusted EBITDA, supported by a modest inventory build and capital expenditures of up to about $140 million.
Several factors will determine whether the company meets that outlook. The first centers on Hopewell, where key productivity investments are now complete and the focus has shifted to execution and ramping production. Second, investors should track demand signals in pharma and personal care, which have been the strongest growth engines, along with any recovery in energy and resources end markets.
Currency is another variable: recent dollar strength is expected to reduce fiscal 2027 sales by about $20 million to $25 million and adjusted EBITDA by $7 million to $10 million. Finally, pricing actions taken in the second half of fiscal 2026 will need to keep offsetting raw material inflation. With net leverage at 2.3x and total liquidity near $976 million, Ashland enters the new fiscal year with meaningful financial flexibility.
Using Tickeron AI Tools for Deeper Analysis
In my own research workflow, I often turn to Tickeron’s AI Screener to quickly filter stocks by industry, technical patterns, fundamentals, and AI-driven signals. It helps surface comparable names and potential trade ideas without manual effort, letting me cross-check earnings trends and valuation metrics more efficiently. The platform’s customizable filters have become a regular part of evaluating specialty chemical names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ASH in upward trend: 10-day moving average broke above 50-day moving average on October 22, 2026
The 10-day moving average for ASH crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on ASH as a result. In 50 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for ASH just turned positive on October 06, 2026. Looking at past instances where ASH's MACD turned positive, the stock continued to rise in 29 of 54 cases over the following month. The odds of a continued upward trend are 54%.
ASH moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASH advanced for three days, in 150 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 76 of 190 cases where ASH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 40%.
Bearish Trend Analysis
The 10-day RSI Indicator for ASH moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 10 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 45%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
ASH broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. ASH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.817) is normal, around the industry mean (2.436). P/E Ratio (70.657) is within average values for comparable stocks, (-18.867). Projected Growth (PEG Ratio) (0.090) is also within normal values, averaging (1.548). Dividend Yield (0.023) settles around the average of (0.039) among similar stocks. P/S Ratio (1.731) is also within normal values, averaging (48.960).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Should I Trust an Article Such as “What Are the Best Mutual Funds?”
Getting Started with Options Trading: What Are the Key Considerations for Warrants?
AI Trading Bots: Top 10 Swing Traders, Virtual Accounts, on December 27, 2024
Q1 2026 Earnings Preview: April 27 – May 1, 2026 | VZ, GOOGL, MSFT, AAPL, META, AMZN, LLY, V, MA
Rising Flag (Bullish) Pattern Explained
General Information
a manufacturer of specialty ingredients, performance materials and valvoline
Industry ChemicalsSpecialty
Advertisement